Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

0.3018 -0.0069 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharma CS

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Down 1%; Dow Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
Marinus Pharmaceuticals stock plummeted after disappointing data from the Phase 3 TrustTSC trial of ganaxolone for seizures linked to tuberous sclerosis complex. 
Via Benzinga
Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results
Via Benzinga
Dow Falls 150 Points; Tesla Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
From Marinus Pharmaceuticals
Via Business Wire
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success. 
Via MarketBeat
Topics ETFs
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications. 
Via MarketBeat
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024
MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
3 Biotech Stocks to Sell in August Before They Crash & Burn
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains. 
Via InvestorPlace
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Teradata, and Lamb Weston and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
From The Law Offices of Frank R. Cruz
Via Business Wire
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus
From Faruqi & Faruqi LLP
Via GlobeNewswire
MRNS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS
From The Rosen Law Firm PA
Via GlobeNewswire
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Humana, and Lamb Weston and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.